Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: Results of a large, multicentre phase II study

1. Morales, S.
2. Lorenzo, A.
3. Ramos, M.
4. Ballesteros, P.
5. Méndez, M.
6. Almanza, C.
7. Castellanos, J.
8. Moreno-Nogueira, J.A.
9. Casal, J.
10. Lizón, J.
11. Oltra, A.
12. Frau, A.
13. Machengs, I.
14. Galán, A.
15. Belón, J.
16. Llorca, C.